

Thomas F Rogers

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2277683/thomas-f-rogers-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

2,307
citations

16
h-index

33
g-index

33
ext. papers

3,413
ext. citations

20.4
avg, IF

4.75
L-index

#	Paper	IF	Citations
31	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , 2020 , 369, 956-963	33.3	906
30	Animal models for COVID-19. <i>Nature</i> , 2020 , 586, 509-515	50.4	377
29	Structural basis of a shared antibody response to SARS-CoV-2. <i>Science</i> , 2020 , 369, 1119-1123	33.3	338
28	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <i>Nature Communications</i> , 2021 , 12, 2938	17.4	110
27	Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	69
26	Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. <i>Science Immunology</i> , 2017 , 2,	28	68
25	Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. <i>Nature Communications</i> , 2021 , 12, 6055	17.4	56
24	Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. <i>Nature Communications</i> , 2018 , 9, 1624	17.4	50
23	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection 2020 ,		40
22	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. <i>Nature Communications</i> , 2020 , 11, 6121	17.4	36
21	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model 2020 ,		35
20	Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. <i>Cell Reports</i> , 2021 , 35, 108940	10.6	28
19	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes 2021 ,		26
18	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. <i>Nature Communications</i> , 2021 , 12, 3309	17.4	25
17	Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19. <i>ELife</i> , 2021 , 10,	8.9	18
16	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj5413	17.5	18
15	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. <i>Science Translational Medicine</i> , 2022 , 14, eabi9215	17.5	15

14	Adult Stem Cell-derived Complete Lung Organoid Models Emulate Lung Disease in COVID-19 2021 ,		15
13	Structural basis of a public antibody response to SARS-CoV-2 2020 ,		14
12	AI-guided discovery of the invariant host response to viral pandemics. <i>EBioMedicine</i> , 2021 , 68, 103390	8.8	13
11	Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19		10
10	Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine 2020 ,		8
9	AI-guided discovery of the invariant host response to viral pandemics 2021 ,		6
8	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants 2021 ,		6
7	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques		4
6	Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. <i>Cell</i> , 2021 , 184, 6022-6036.e18	56.2	3
5	Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections. <i>Viruses</i> , 2020 , 12,	6.2	3
4	Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses. 2022 ,		3
3	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. 2022 ,		2
2	Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection. 2022 ,		1
1	A novel CSP C-terminal epitope targeted by an antibody with protective activity against <i>Plasmodium falciparum</i> .. <i>PLoS Pathogens</i> , 2022 , 18, e1010409	7.6	0